Welcome to our dedicated page for Moolec Science news (Ticker: MLEC), a resource for investors and traders seeking the latest updates and insights on Moolec Science stock.
Moolec Science SA (NASDAQ: MLEC) generates news at the intersection of food-tech, life sciences, and agricultural biotechnology. The company regularly issues updates on how it engineers plants and microbes to produce animal proteins, nutritional oils, bioactive compounds, and biological inputs for regenerative agriculture through its Molecular Farming and precision fermentation platforms.
News about Moolec often covers progress in its key ingredient programs, such as its GLASO safflower technology enriched in gamma-linolenic acid and its Piggy Sooy™ soybean platform engineered to express porcine hemeproteins. Press releases have highlighted regulatory approvals, including feed and food approval for GLASO technology in Argentina and U.S. regulatory milestones for Piggy Sooy™, as well as large-scale agricultural campaigns and acreage expansion in the United States.
Investors and industry observers can also find coverage of Moolec’s corporate and strategic developments. Recent announcements include the closing of a strategic business combination with Bioceres Group Limited, Gentle Technologies Corp, and Nutrecon LLC, which expanded Moolec’s activities into ag-biologicals, biomaterials, and R&D services. The company also reports on the integration of Mycofood™, its fungal-based alternative protein platform produced via precision fermentation.
Moolec’s news flow additionally includes capital markets and compliance updates, such as Nasdaq determination letters related to minimum bid price, stockholders’ equity, and filing timelines, as well as share consolidations and reverse stock splits intended to support continued listing on the Nasdaq Capital Market. For readers tracking MLEC, this news page provides a centralized view of operational milestones, regulatory events, strategic transactions, and listing-related actions that shape the company’s trajectory in the food-tech and life sciences sectors.
Moolec Science SA (NASDAQ:MLEC) has announced the upcoming harvest of its genetically engineered plant-grown products GLASO™ and Piggy Sooy™ in October 2024. The GLASO™ campaign in Idaho covers 600 acres and is expected to yield 300-400 tons of high-GLA safflower seeds. Moolec has secured an offtake agreement with a major global CPG company for GLASO™, targeting the US market in 2025. Piggy Sooy™ field trials are being conducted in Ohio, Missouri, and Iowa for product development, seed increase, and regulatory data gathering. Moolec recently obtained USDA-APHIS approval for Piggy Sooy™ cultivation, marking a significant milestone in Molecular Farming. The company aims to provide sustainable solutions in agriculture and biotechnology, with Piggy Sooy™ potentially producing pork meat proteins equivalent to 10 pigs per acre while reducing environmental impact.
Moolec Science SA (NASDAQ:MLEC) has signed a three-year offtake agreement with a major global consumer packaged goods and pet food company for its GLASO™ product, a high-GLA safflower oil. The agreement covers US territory with an initial estimated volume of 50 tons for 2025. GLASO™ contains almost 3 times more GLA than conventional sources, making it the most concentrated GLA oil available.
Moolec has also secured agreements with farmers for safflower cultivation and an industrial partner for downstream processing, ensuring a controlled supply chain. This milestone demonstrates Moolec's ability to scale production and meet growing demand for sustainable nutritional ingredients.
Moolec Science (NASDAQ:MLEC) has released its business update for the third quarter of Fiscal Year 2024, ending March 31, 2024. Key highlights include the USDA-APHIS regulatory approval of their patented soybean product, Piggy Sooy™, and progress in the GLASO™ safflower platform. Financially, normalized revenues and other income increased by approximately $1.3 million year-over-year due to the consolidation of the soy-protein ingredient business. However, R&D, administrative, and other expenses rose to $2.3 million, a 68% year-over-year increase, largely due to non-cash items. Operational cash utilization for the quarter was around $2.6 million, with $1.4 million allocated to reducing accounts payable. CEO Gastón Paladini and CFO José López Lecube expressed optimism about the company's achievements and future prospects.
Moolec Science (NASDAQ: MLEC), a company specializing in Molecular Farming to produce animal proteins in plants, will release its Third Quarter Fiscal Year 2024 Business Update on May 30, 2024, before market opening.
CEO Gastón Paladini, CFO José López Lecube, and CSO Amit Dhingra will host a live conference call at 08:30 a.m. ET the same day, followed by a Q&A session. The conference call will feature a presentation available during the webcast, with a replay and PDF version accessible two hours post-event on the company's Investor Relations website.
Moolec Science SA (NASDAQ: MLEC) announced the granting of a patent in the United States for its SPC2 product produced in safflower with Molecular Farming technology. This patent provides exclusivity until 2041, showcasing Moolec's innovative approach in the industrial biotech sector. The technology involves safflower plants engineered with DNA sequences to enhance bovine chymosin expression, paving the way for new proteins and products. Moolec's Chief Science Officer highlighted the significance of this patent in expanding opportunities for the company's safflower platform and driving innovation in sustainable biotechnology.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.